UNIVERSITY OF COLORADO SCHOOL OF MEDICINE



UNIVERSITY OF COLORADO SCHOOL OF MEDICINE

1. Personal history

• Associate Professor, Division of Hematology

2. Education

• Princeton University; History major; Magna Cum Laude; 1992-1996

• Goucher College Post-Baccalaureate Pre-medical Program; 1996-1997

• New York University School of Medicine; 1998- 2002

• University of Colorado Internal Medicine Residency Program; 2002-2005

• University of Washington/Fred Hutchinson Cancer Research Center Medical Oncology Fellowship; 2006-2009

3. Academic appointments

• University of Colorado, Assistant Professor, Division of Medical Oncology; 2009-2015

• University of Colorado, Associate Professor, Division of Hematology; 2015-present

• Affiliate Investigator, Fred Hutchinson Cancer Research Center, 2009-2014

4. Hospital, government or other professional positions

• Co-Medical Director, University of Colorado Cord Blood Bank, 2009-present

• Colorado Multiple Institution Review Board, Member 2010-2014

• University of Colorado Cancer Center Scientific Review Committee, Member 2011-2012

• Laboratory Medical Director, University of Colorado Clinical Stem Cell Laboratory 2011-present

• Director of Allogeneic Stem Cell Transplantation, University of Colorado 2012-present

• Chairman, University of Colorado Cancer Center Protocol Review and Monitoring System 2012-2016

• Director, Hematology Division Education 2014-present

5. Honors, special recognitions and awards

• Lucien J. Rubinstein Memorial Award, Best American Brain Tumor Association Medical Student Fellowship Research Project, 2000

• University of Colorado Cancer Center award for outstanding leadership of PRMS, 2016

• Division of Hematology Spotlight Award for outstanding contribution to the division, 2018

6. Membership in professional organizations

• American Society of Hematology, 2006-present

• American Society of Clinical Oncology, 2006-present

• American Society for Blood and Marrow Transplantation, 2009-present

7. Major Committee and Service Responsibilities

• Founder and president, The Survivor Fund (501C3 that remains currently active dedicated to fundraising for the Bellevue/NYU Program for Survivors of Torture), 1998-2002

• National Cord Blood Program Data Safety Monitoring Board, 2013-present

• American Society for Blood and Marrow Transplantation, Committee on Research Priorities, 2013-present

• American Society for Blood and Marrow Transplantation, Cellular Therapy Task Force, 2013-present

• NCCN Hematopoietic Stem Cell Transplant Panel, 2018-present

8. Licensure and board certification

• Board certified in Internal Medicine, American Board of Internal Medicine; 2005

• Board certified in Medical Oncology, American Board of Internal Medicine; 2009

9. Review and referee work

• Grant review committies:

NHS Leukemia Research Foundation Clinical Trials Advisory Panel 2009

Amy Strelzer Manasevit Grant Committee 2014-present

• Leukemia and Lymphoma Society Therapy Acceleration Program review 2016

• Ad hoc reviewer:

Bone Marrow Transplantation 2010-present

Biology of Blood and Marrow Transplantation 2010-present

Cytotherapy 2015

Blood Reviews 2018-present

10. Invited extramural lectures, presentations and visiting professorships

Adult Cord Blood Transplant: What, why, when, who…and where are we going?

Vail Valley Medical Center, Vail11/30/2009

Penrose Hospital, Colorado Springs 1/27/2010

Montrose Memorial Hospital, Montrose 8/6/2010

St Mary’s Hospital, Grand Junction 9/2/2010

Denver Health, Denver 9/9/2010

Colorado Cytogenetics Lab 2011

Hematopoietic Stem Cell Transplantation

Chimerix national meeting 6/1/2010

Graft Versus Host Disease

CIGNA transplant program annual meeting 4/14/2012

Follicular Lymphoma Overview

Follicular Lymphoma Treatment

Lymphoma Research Foundation 6/14/13

Allogeneic Transplant Infectious Disease

St Mary’s Hospital, Grand Junction 2/17/2014

Adult Acute Leukemia: Rocky Mountain Blood Cancer Conference

Leukemia and Lymphoma Society 4/11/15

Transplant for MDS

MDS Patient Forum 10/29/2016

Introduction to Chronic GVHD

2018 Celebrating a Second Chance at Life Survivorship Symposium 4/28/2018

Cord blood transplantation: the good, the issues, and the future

Arizona Cord Blood Conference 4/4/2019

11. Teaching record

• Major presentations to medical students, graduate students, house officers:

Adult Cord Blood Transplant: What, why, when, who…and where are we going?

Department of Medicine Grand Rounds 11/4/2009

Department of Radiation Oncology Grand Rounds 2/4/2010

Clinimmune Labs 11/10/2010

Department of Obstetrics and Gynecology Grand Rounds 3/21/2011

Allogeneic Stem Cell Transplant 101 (with an ID emphasis)

Division of Infectious Disease Grand Rounds 9/19/2012

Allogeneic Hematopoietic Stem Cell Transplantation

Clinicopathologic Conference, Department of Pathology 10/1/2012

T cells after stem cell transplant: Can we make them better faster

Department of Medicine Innovations in Medicine 2/21/2013

Acute Myeloid Leukemia

Heme Malignancy/BMT Program Grand Rounds 11/2/2009

Introduction to Hematopoietic Stem Cell Transplantation

Heme Malignancy/BMT Program Grand Rounds 3/5/2010, 11/15/2011, 9/17/2012, 9/26/2013, 10/17/2014, 10/25/16, 11/10/17

Hematology/Oncology Fellows 10/20/14

Radiation Oncology Residents 6/8/2017

Infectious Disease Fellows 11/28/2017, 8/27/2018

Hematopoietic Stem Cell Transplantation Complications

Heme Malignancy/BMT Program Grand Rounds 8/31/2010, 11/29/2011, 2/17/2015

Graft Versus Host Disease

Heme Malignancy/BMT Program Grand Rounds 11/5/2012, 2/3/15, 11/20/17

Cord Blood Transplantation

Heme Malignancy/BMT Program Grand Rounds 9/7/2010, 12/6/2011, 8/23/2012, 9/20/2013, 9/4/2014

Hematology/Oncology Fellows 9/4/2014, 10/9/2015

A Season by Everest: Medicine in the Khumbu

Clinimmune Labs 2/23/2011

Heme Malignancy/BMT Program Grand Rounds 5/14/2013, 12/2/2013, 5/21/2017

Hematologic Malignancies Overview

Fellows Grand Rounds 7/3/2013, 7/5/2014

Allogeneic Transplantation Infectious Disease

Heme Malignancy/BMT Program Grand Rounds 2/9/2015

Infectious Disease Fellows 11/21/2014

Hematology/Oncology Fellows 1/11/2018

Aplastic Anemia

Heme Malignancy/BMT Program Grand Rounds 1/3/2015

Non-GVHD, Non- Infectious Complications of Stem Cell Transplant

Heme Malignancy/BMT Program Grand Rounds 2/17/2015, 11/28/2017

Leukemia and Lymphoma

Resident Didactic 9/14/2015

A Case Based Approach to Common Issues Encountered in Allogeneic Transplant Patients General Internal Medicine Grand Rounds 9/6/2016

GVHD

Nursing Education Conference 10/18/2016, 4/13/2017, 5/23/2018

ICU Complications of Stem Cell Transplant

Internal Medicine Residents 6/15/2017

Palliative Care in Stem Cell Transplant

Palliative Care Grand Rounds 9/18/2017

• Pathology 8001”Interpreting laboratory testing”

HLA testing 10/4/2010, 10/16/2011, 9/19/2012, 9/24/2014, 9/14/15

Laboratory management of AML 10/4/2010, 10/16/2011, 9/19/2012, 9/24/2014, 9/14/15

Cases in Acute Leukemia 10/4/2010, 10/16/2011, 9/19/2012, 9/24/2014, 9/14/15

• Ward/clinic attending duties 2009-present: I have been the ward attending for the BMT inpatient unit for 14-18 weeks each year. I maintain 3 half day outpatient clinics.

• Key administrative positions: Director of Education, Division of Hematology 2014-present (ad hoc 2009-2014)

• Specific accomplishments: I have overseen re-integration of fellow training into the Hematologic Malignancy/BMT training program. I have designed the fellow one month rotation and organized didactic lectures for all hematologic malignancies.

12. Grant support

Angiocrine Biosciences (local PI), 17-2078, 1/29/2018 - 1/28/2023

A Phase 1B Open Label, Multi-center Trial of AB-11 in Adults with Hematologic Malignancies Undergoing Cord Blood Transplantation

Direct $525,500, Indirect $147,140

Incyte Corp.(local PI), 17-2075, 05/21/2018 to 05/20/2023

Itacitinib in Combination with Calcineurin Inhibitor-Based Interventions for the Prophylaxis of GVHD

Direct $292,770, Indirect $81,975

Incyte Corp. (local PI), 17-0745, 10/24/2017 to 10/23/2022,

GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids for the Treatment of First-line Acute GVHD

Direct $368,445, Indirect $95,796

Completed:

Chimerix (local PI) 5/7/14—5/6/17

A Prospective Observational Study for the Long-Term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001 (The Chimerix CMX001 Registry)

Direct $46,003 Indirect $11,196

FHCRC106969-02 Gutman (local PI) Correlating TCR diversity to immune reconstitution after cold blood transplant

Subaward $22,221

PCORI CE-1304-6208 Gutman (Co-investigator) 10/1/13-9/30/16

Multisite randomized controlled trial of an improved psychoeducation program for caregivers with a focus on improving patient outcomes when the caregiver is less distressed.     

$487,934 (current year)                             

Chimerix Gutman (local PI) 7/16/13—7/15/16

A randomized, double-blind, placebo-controlled, parallel-group, multicenter phase 3 study of the safety, tolerability, and efficacy of CMX001 for the prevention of cytomegalovirus (CMV) infection on CMV-seropositive hematopoietic stem cell transplant recipients

Direct $282,473, Indirect $34,227

GSK PHS 3 Gutman (local PI) 3/15/13-3/14/16

A phase III, randomised, observer-blind, placebo-controlled, multicentre, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals' herpes zoster gE/AS01B candidate vaccine when administered intramuscularly on a two-dose schedule to adult autologous haematopoietic stem cell transplant (HCT) recipients

Direct $89,280, Indirect $18,634

1P50HL110787-01 Gutman (local PI) 05/16/2012 – 04/30/2017

|Multi-center, open-label randomized study of single or double myeloablative cord blood transplantation with or without infusion of off–the-shelf ex |

|vivo expanded cryopreserved cord blood progenitor cells in patients with hematologic malignancies |

|Subaward $50,886 |

GG80 Gutman (local PI) 1/15/10-12/31/13

A multicenter, randomized, double-blind, placebo-controlled, dose escalation study of the safety, tolerability, and ability of CMX001 to prevent or control CMV infection in R+ hematopoietic stem cell transplant recipients.

Direct $74,800, Indirect $5,200

1RC2HL101844 Gutman (local PI) 9/1/10-8/31/12

Notch mediated expansion of cord blood progenitors for cord blood transplantation

Direct $34,851, Indirect $9,061

DK56465 Gutman (PI) 11/2007-11/2008

Core Center of Excellence in Hematology Pilot Grant, Fred Hutchinson Cancer Research Center/University of Washington 11/2007-11/2008 (co-investigator): Investigation of an immunologic basis for the emergence of a dominant unit in double cord blood transplantation

Award: $35,000

UL1RR025014 Gutman (PI) 5/2008-5/2009

Institute of Translational Health Sciences Small Pilot Grant, National Center for Research Resources 5/2008-5/2009 (co-investigator): Investigation of an Immunologic Basis for the Emergence of a Dominant Unit in Double Cord Blood Transplantation

Award: $35,000

American Brain Tumor Association Student Research Fellowship 2001: HIF-1 regulation is not affected by p53 or PTEN mutations in glioblastoma cell lines

13. Bibliography

Peer reviewed journals:

1. Olson AL, Gutman JA, Welsh C. A fifty year old male with skin lesions and multiple pulmonary nodules. Chest 2004;125:2322-2327.

2. Gutman JA, Bearman S, Nieto Y, Sweetenham JW, Jones RB, Shpall EJ, Zheng C, Baron A, McSweeney P. Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma: a feasibility study. Bone Marrow Transplantation 2005; 36: 443-451.

3. Gutman JA, Shpall EJ, Nieto Y, McSweeney P, McNiece I. Long-term follow up of breast cancer patients transplanted with autologous ex vivo expanded peripheral blood progenitor cells. Cell Preservation Technology 2006; 4: 4-8.

4. Fagenholz PJ, Gutman JA, Murray AF, Noble VE, Thomas SH, Harris NS. Chest ultrasonography for the diagnosis and monitoring of high altitude pulmonary edema. Chest 2007;131:1013-1018.

5. Fagenholz PJ, Gutman JA, Murray AF, Harris NS. Treatment of high altitude pulmonary edema at 4240m in Nepal. High Altitude Medicine and Biology 2007;8:139-146.

6. Gutman JA, Peck AJ, Kuypers J, Boeckh M. Rhinovirus as a cause of fatal lower respiratory tract infection in adult stem cell transplantation patients: a report of two cases. Bone Marrow Transplant 2007;40:809-811.

7. Fagenholz PJ, Murray AF, Gutman JA, Findley J, Harris NS. New onset anxiety disorders at high altitude. Wilderness and Environmental Medicine 2007;18:312-316.

8. Fagenholz PJ, Gutman JA, Murray AF, Noble VE, Wu A, Ziemer G, Harris NS. Arterial thrombosis at high altitude resulting in loss of limb. High Altitude Medicine and Biology 2007;8:340-347.

9. Fagenholz PJ, Gutman JA, Murray AF, Noble VE, Camargo CA, Harris NS. Evidence for increased intracranial pressure in high altitude pulmonary edema. High Altitude Medicine and Biology 2007;8:331-336.

10. Gutman JA, Allen CT, Madtes DK, Schramm J, Delaney C. Pulmonary veno-occlusive disease following reduced-intensity cord blood transplantation. Bone Marrow Transplant 2008;42:559-61.

11. Gutman JA, McKinney SK, Warnock SL, Smith AG, Woolfrey AE, Hansen JA, and Delaney C. Prospective monitoring for alloimmunization in cord blood transplantation: “virtual crossmatch” can be used to demonstrate donor-directed antibodies. Transplantation 2009;87:415-8.

12. Fagenholz PJ, Gutman JA, Murray AF, Noble VE, Camargo CA, Harris NS. Optic nerve sheath diameter correlates with the presence and severity of acute mountain sickness: evidence for increased intracranial pressure. Journal Applied Physiology 2009;106:1207-11.

13. Gutman JA, Leisenring W, Appelbaum FR, Woolfrey AE, Delaney C. Low relapse without excessive transplant related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis. Biology of Blood and Marrow Transplant 2009;15:1122-9.

14. Delaney C, Gutman JA, and Appelbaum FR. Cord blood transplantation for hematologic malignancies: conditioning regimens, double cord transplant, and infectious complications. British Journal of Haematology, 2009;147:207-16.

15. Gutman JA, Turtle CJ, Manley TJ, Heimfeld S, Bernstein IR, Riddell SR, and Delaney C. Single unit dominance following double unit umbilical cord blood transplantation coincides with a specific CD8+ T cell response against the non-engrafted unit. (Plenary paper) Blood 2010;115:757-65.

16. Brunstein CG, Gutman JA, Defor TE, Gooley T, Verneris MR, Woolfrey A, Weisdorf DJ, Appelbaum FR, Wagner JE, Delaney C. Allogeneic hematopoietic cell transplantation for hematological malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010;116;4693-9.

17. Gutman JA, Miller S, Kuenne S, Oppenheim J, Stark C, Zarlengo G, Quinones R, Freed BM. Cord blood collection after cesarean section improves banking efficiency. Transfusion 2011;51:2050-1.

18. Milano F, Pergam SA, Xie H, Leisenring WM, Gutman JA, Riffkin I, Chow V, Boeckh MJ, Delaney C. Intensive strategy to prevent cytomegalovirus disease in seropositive umbilical cord blood transplant recipients. Blood 2011;118:5689-96.

19. Milano F, Chien JW, Riffkin I, Gutman JA, Newell L, Pergam SA, Delaney C. Stable long-term pulmonary function after myeloablative double cord blood transplant. Biology of Blood and Marrow Transplant 2012;18:309-13.

20. Gutman JA, Hoffner B. A novel CEBPA germline variant in a case of acute myeloid leukemia. Leukemia and Lymphoma 2012;53:1006-7.

21. Petz L, Redei I, Bryson Y, Regan D, Kurtzberg J, Shpall E, Gutman J, Querol S, Clark P, Bravo A, Tonai R, Santos S, Spellman S, Gragert L, Boo M, Rossi J, Li S, Li H, Senitzer D, Rosenthal J, Zaia J, Forman S, Chow R. Hematopoietic cell transplantation with cord blood for cure of HIV infections. Biology of Blood and Marrow Transplant 2013;19:393-397.

22. Ostronoff F, Milano F, Gooley T, Gutman JA, McSweeney P, Petersen F, Sandmaier BM, Storb R, Delaney C. Umbilical cord blood transplantation in patients with hematological malignancies using a non-ATG containing reduced intensity preparative regimen. Bone Marrow Transplantation 2013;48:782-786.

23. Narayanan V, Pollyea DA, Gutman JA, Jimeno A. Ponatinib for the treatment of Ph+ALL and CML. Drugs of Today. 2013;49:261-9.

24. Coffey DG, Pollyea DA, Myint H, Smith C, Gutman JA. Adjusting DLCO for hemoglobin and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index. Bone Marrow Transplantation 2013;48:1253-6.

25. Narayanan V, Gutman JA, Pollyea DA, Jimeno A. Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia. Drugs of Today. 2013;49:447-56.

26. Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, Brundage TM, Robertson AT, Godkin S, Momméja-Marin H, Boeckh M; CMX001-201 Clinical Study Group. (Gutman J 10/26) CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013;369:1227-36.

27. GyurkoczaB, Gutman J, Nemecek ER, Bar M, Milano F, Ramakrishnan A, Scott B, Fang M, Wood B, Pagel JM, Baumgart J, Delaney C, Maziarz RT, Sandmaier BM, Estey EH, Appelbaum FR, Storer BE, Deeg HJ. Treosulfan, Fludarabine and 2 Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with MDS and AML. Biology of Blood and Marrow Transplant. 2014;20:549-55.

28. Pollyea DA, Gutman JA, Gore L, Smith CA, Jordan CT. Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. Haemotologica. 2014;99:1277-84.

29. Babilonia KM, Golightly LK, Gutman JA, Hassell KL, Kaiser JN, Kiser TH, Klem PM, and Trujillo TC. Antithrombotic Therapy in Thrombocytopenic Cancer Patients: Outcomes Associated with Reduced-Dose Low-Molecular Weight Heparin during Hospitalization. Clinical Applied Thrombosis and Hemostasis. 2014;20:799-806.

30. Bird GA, Polsky A, Estes P, Hanlon T, Hamilton H, Morton JJ, Gutman J, Jimeno A, Turner BC, Refaeli Y. Expansion of human and murine hematopoietic stem and progenitor cells ex vivo without genetic modification using MYC and Bcl-2 fusion proteins. PLOS One 2014;9:e105525.

31. Pollyea DA and Gutman JA. Stopping Higher-Risk Myelodsyplastic Syndrome in its Tracks. Current Hematologic Malignancy Reports 2014;9:421-31.

32. Stevens B, Maxson J, Tyner J, Smith CA, Gutman JA, Robinson W, Jordan CT, Lee CK, Swisshelm K, Tobin J, Wei Q, Schowinsky J, Rinella S, Lee HG, Pollyea DA. Clonality of Neutrophilia Associated with Plasma Cell Neoplasms: Report of a SETBP1 Mutation and Analysis of a Single Institution Series. Leuk Lymphoma. 2016 57:927-34.

33. Gavin KM, Gutman JA, Kohrt WM, Wei Q, Shea KL, Miller HL,Sullivan TM, Erickson PF, Helm KM, Acosta AS, Child CR, Musselwhite5 E, Varella-Garcia5 M, Kelly K, Majka SM and Klemm DJ. De Novo Generation of Adipocytes from Circulating Progenitor cells in Human and Mouse Adipose Tissue. FASEB Journal. 2016 30:1096-108.

34. Gutman JA, Ross K, Smith C, Myint H, Lee CK, Salit R, Milano F, Delaney C, Gao D, Pollyea DA. Chronic Graft Versus Host Disease Burden and Late Transplant Complications Are Lower Following Adult Double Cord Blood Versus Matched Unrelated Donor Peripheral Blood Transplantation. Bone Marrow Transplantation. 2016 Dec;51(12):1588-1593.

35. Schade H, Sen S, Neff CP, Freed BM, Gao D, Gutman JA* and Brent E. Palmer*. (Shared senior authorship) PD-1 expression on CD4+ T cells predicts mortality following allogenic stem cell transplantation. Biology of Blood and Marrow Transplant. 2016 Dec;22(12):2172-2179.

36. Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N,Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, Smith C, Jordan CT. Rational Design of a Parthenolide-based Drug Regimen that Selectively Eradicates Acute Myelogenous Leukemia Stem Cells. J Biol Chem. 2016 Oct 14;291(42):21984-22000.

37. Nooruddin Z, Miltgen N, Wei Q, Schowinsky J, Pan Z, Tobin J, Purev E, Gutman JA, Robinson W, Pollyea DA. Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib. Haematoligica. 2017 May;102(5):e207-e209.

38. Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM. PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017 Jul 13;130(2):221-228.

39. Melani C, Major A, Schowinsky J, Roschewski M, Pittaluga S, Jaffe ES, Pack SD, Abdullaev Z, Ahlman MA, Kwak JJ, Morgan R, Rabinovitch R, Pan Z, Haverkos BM, Gutman JA, Pollyea DA, Smith CA, Wilson WH, Kamdar M. PD-1 Blockade in Mediastinal Gray-Zone Lymphoma. N Engl J Med. 2017 Jul 6;377(1):89-91.

40. Sharma P, Pollyea DA, Smith CA, Purev E, Kamdar M, Haverkos B, Sherbenou D, Rabinovitch R, Hammes A, Gutman JA. Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison. Biol Blood Marrow Transplant. 2018 Aug;24(8):1671-1677

41. Daniel A. Pollyea, Brett M. Stevens, Courtney L. Jones, Amanda Winters, Shanshan Pei, Mohammad Minhajuddin, Angelo D’Alessandro, Rachel Culp-Hill,Kent A. Riemondy, Austin E. Gillen, Jay R. Hesselberth, Diana Abbott5, Derek Schatz, Jonathan A. Gutman, Enkhtsetseg Purev, Clayton Smith, Craig T. Jordan. Venetoclax with Azacitidine Disrupts Energy Metabolism and Targets Leukemia Stem Cells in Acute Myeloid Leukemia Patients. Nature Medicine. 2018 Dec;24(12):1859-1866.

42. Brett Stevens, Amanda Winters, Jonathan A. Gutman, Aaron Fullerton, Gregory Hemenway, Derek Schatz, Nicholas Miltgen, Qi Wei, Taher Abbasi, Shireen Vali, Neeraj K Singh, Leylah Drusbosky, Christopher R. Cogle, Andrew Hammes, Diana Abbott, Craig T. Jordan, Clayton Smith, Daniel A. Pollyea.Sequential Azacitidine and Lenalidomide for Patients with Relapsed and Refractory Acute Myeloid Leukemia: Clinical Results and Predictive Modeling Using Computational Analysis. Leukemia Research. 2019

43. Brenda M Sandmaier, MD; Brian Kornblit; Barry E Storer;

Gitte Olesen; Michael B Maris; Amelia A Langston; Jonathan A Gutman;Søren L Petersen; Thomas R Chauncey; Woflgang A Bethge; Michael A Pulsipher; Ann E Woolfrey; Marco Mielcarek; Paul J Martin; Frederick R Appelbaum; Mary E Flowers; David G Maloney; Rainer StorbEffectiveness of addition of sirolimus to cyclosporine and mycophenolate mofetil-based graft-versus-host disease prophylaxis after unrelated nonmyeloablative hematopoietic cell transplantation: A multicentre phase III randomized trial. Lancet Hematology. 2019.

Book chapters, invited articles & reviews in non peer-reviewed journals

1. Gutman JA, Riddell SR, McGoldrick S, Delaney C. Double unit cord blood transplantation: Who wins – and why do we care? Chimerism 2010;1:21-23.

2. Gutman JA. Are there any pulmonary issues specifically related to cord blood transplants? In: Azoulay E (ed) Pulmonary Involvement in Patients with Hematological Malignancies. Springer- Verlag Berlin Heidelberg 2011.

3. Gutman JA. Pulmonary veno-occlusive disease. In: Azoulay E (ed) Pulmonary Involvement in Patients with Hematological Malignancies. Springer- Verlag Berlin Heidelberg 2011.

4. Gutman JA, Heimfeld S, and Deeg HJ. Alternative sources of hematopoietic stem cells and their clinical applications. In: Wiernik P, Goldman J, Dutcher J, Kyle R (eds) Neoplastic Diseases of the Blood, 5th edition. Springer 2011.

5. Gutman JA, Smith K, and Pagel J. Chronic lymphocytic leukemia. In: Estey E and Appelbaum FR (eds) Leukemia and Related Disorders: Integrated Treatment Approaches. Humana Press 2012.

6. Newell LF, Gutman JA, Delaney C. Hematopoietic stem cell transplantation alternate donors – a role for umbilical cord blood transplantation for hematologic malignancies. In: Estey E and Appelbaum FR (eds) Leukemia and Related Disorders: Integrated Treatment Approaches. Humana Press 2012.

7. Petz LD, Burnett J, Li H, Li S, Tonai R, Baklinskaya M, Shpall E, Armitage S, Kurtzberg J, Regan D, Clark P, Querol S, Gutman J, Spellman S, Gragert L, Rossi J. Progress toward Curing HIV with Hematopoietic Cell Transplantation. Stem Cells and Cloning: Advances and Applications 2015;8:109-116

8. Ross, K and Gutman JA. Cord blood conditioning regimens. In: Horwitz, Chao Cord Blood Transplantation. Springer 2017.

Scientific abstracts published or presented at scientific meetings

1. Fagenholz PJ, Gutman JA, Murray AF, Noble VE, Wu A, Harris NS. Peripheral arterial thromboembolism at high altitude: report of a case and the application of ultrasound in a remote high altitude setting. 15th International Hypoxia Symposium, 2007. High Altitude Medicine and Biology 2006; 7: 327. Poster

2. Fagenholz PJ, Gutman JA, Murray AF, Harris NS. Treatment of high altitude pulmonary edema is feasible at 4240 m with delayed rather than immediate descent. 15th International Hypoxia Symposium, 2007. High Altitude Medicine and Biology 2006; 7: 327. Poster

3. Fagenholz PJ, Gutman JA, Murray AF, Noble VE, Harris NS. Optic nerve sheath ultrasonography can be used to monitor intracranial pressure in high altitude cerebral edema. 15th International Hypoxia Symposium, 2007. High Altitude Medicine and Biology 2006; 7: 327-328. Oral

4. Fagenholz PJ, Gutman JA, Murray AF, Noble VE, Harris NS. Optic nerve sheath diameter is increased in high altitude pulmonary edema: evidence for increased intracranial pressure. 15th International Hypoxia Symposium, 2007. High Altitude Medicine and Biology 2006; 7: 328-329. Poster

5. Fagenholz PJ, Gutman JA, Murray AF, Noble VE, Thomas SH, Harris NS. Chest ultrasonography effectively identifies and monitors extravascular lung water in high altitude pulmonary edema. 15th International Hypoxia Symposium, 2007. High Altitude Medicine and Biology 2006; 7: 328. Oral

6. Fagenholz PJ, Gutman JA, Murray AF, Noble VE, Camargo CA, Pelletier AJ, Harris NS. Optic nerve sheath diameter, a surrogate measure of intracranial pressure, is associated with the presence and severity of acute mountain sickness. 15th International Hypoxia Symposium, 2007. High Altitude Medicine and Biology 2006; 7: 328. Oral

7. Gutman JA, Gooley TA, Nourigat J, Pagel JM, Press OW, Holmberg LA, Bensinger WI, Petersdorf SH, Gopal AK. High-dose therapy and autologous stem cell transplantation for chemoresistant diffuse large B cell lymphoma: the Seattle experience. ASH. Blood 2007;110

8. Gutman JA, McKinney SK, Warnock SL, Smith A, Woolfrey AE, Hansen JA, Delaney C. Monitoring for HLA antibodies in cord blood transplantation. ASH Blood 2007;110: a2031. Poster

9. Gutman JA, Woolfrey AE, Appelbaum FR, Sandmaier BM, Sanders JE, Delaney C. Outcomes in the recent Seattle cord blood experience: Low TRM and relapse; high mild acute GVHD and CMV reactivation. ASH Blood 2007;110: a2019. Poster

10. Delaney C, Stein C, Voorhies H, Gutman JA, Heimfeld S, Dallas M, Bernstein I. Notch-mediated expansion of human cord blood progenitor cells results in rapid myeloid reconstitution in vivo following myeloablative cord blood transplantation. ASH. Blood 2008; 112: a212. Oral

11. Gutman JA, Olson AL, Lee SJ, Sandmaier BM, Storb R, Appelbaum FR, Delaney C. Adult cord blood transplantation (CBT) vs. unrelated donor transplantation: a cost comparison. ASH. Blood 2008; 112: a2383. Poster

12. Gutman JA, Leisenring W, Appelbaum FR, and Delaney C. Decreased relapse rates without excessive transplant related mortality following cord blood transplantation (CBT): a matched cohort analysis comparing myeloablative cord, matched unrelated, and mismatched unrelated donor transplants. ASH 2008. Poster

13. Gutman JA, Turtle C, Manley T, Riddell SR, Heimfeld S, and Delaney C. Emergence of the dominant unit following double unit cord blood transplantation is associated with development of an interferon-γ secreting CD8+ T cell population targeting the losing unit. ISCT 2009. Oral

14. Brunstein CG, Gutman JA, Defor TE, Gooley T, Verneris MR, Woolfrey A, Weisdorf DJ, Appelbaum FR, Wagner JE, Delaney C. Reduced relapse and similar progression-free survival after double umbilical cord blood transplantation (DUCBT): comparison of outcomes between sibling, unrelated adult and unrelated DUCB hematopoietic stem cell (HSC) donors. ASH 2009. Oral

15. Miller CN, Miller SN, Flannery S, Stockinger S, Gutman JA, Quinones R, Freed BM. Relative efficiency of cord blood RBC depletion by SEPAX elutriation and manual reduction. ASBMT Biology of Blood and Marrow Transplant 2010;16:S212-213. Poster

16. Newell LF, Gutman JA, Milano F, Riffkin I, Lopez MJ, Ziegler D, Nemecek ER, Delaney C. Treosulfan-based Conditioning is Sufficient to Promote Engraftment in Cord Blood Transplantation. International Cord Blood Symposium 2010. Poster

17. Milano F, Pergam SA, Xie H, Gutman JA, Riffkin I, Newell LF, Boeckh MJ, Delaney C. Pre-Transplant Ganciclovir and High-Dose Acyclovir Decrease Incidence of CMV Reactivation in Seropositive UCBT Recipients. International Cord Blood Symposium 2010. Poster

18. Milano F, Pergam SA, Xie H, Gutman JA, Riffkin I, Chow V, Newell LF, Boeckh MJ, Delaney C. Pre-Transplant Ganciclovir and High-Dose Valacyclovir Prophylaxis Decrease Incidence of CMV Reactivation in High-risk Seropositive UCBT Recipients. ASH 2010. Oral

19. Milano F, Riffkin I, Newell LF, Gutman JA, Chien JW, Delaney C. Stable Pulmonary Function Observed Over Time in Recipients of Myeloablative Double Cord Blood Transplant: a Single Center Experience. ASBMT Biology of Blood and Marrow Transplant 2011;17:S241-242. Poster

20. Newell LF, Milano F, Gutman JA, Riffkin I, Lopez MJ, Ziegler D, Nemecek ER, Delaney C. Treosulfan-based Conditioning is Sufficient to Promote Engraftment in Cord Blood Transplantation. ASBMT Biology of Blood and Marrow Transplant 2011;17:S227-228. Oral

21. Petz L, Tonai R, Li S, Li H, Bryson Y, Regan D, Spellman S, Gragert L, Boo M, Gutman J, Armitage S, Shpall E, Lin A, Rosenthal J, Zaia J, Kurtzberg J, Rossi J, Forman S, Chow R. The Unique Role of Cord Blood Transplants in the Long Term Control or Possible Cure of HIV-Infected Patients. World Stem Cell Summit 2011. Poster

22. Ostronoff F, Milano F, Gooley T, Gutman J, McSweeney PA, Petersen F, Sandmaier BM, Storb R, Delaney C. Umbilical Cord Blood Transplantation in Patients with Hematological Malignancies Using a Non-ATG Containing Reduced Intensity Preparative Regimen. ASH 2011. Poster

23. Milano F, Deeg JH, Gutman JA, Eneida, NR, Delaney, C. Treosulfan-Based Conditioning for Umbilical Cord Blood Recipients Is Safe and Effective: Results from an Ongoing Phase-II Study. ASBMT Biology of Blood and Marrow Transplant 2012;16:S337. Poster

24. Petz L, Tonai R, Redai I, Li S, Li H, Bryson Y, Regan D, Spellman S, Gragert L, Boo M, Gutman J, Armitage S, Shpall E, Lin A, Rosenthal J, Zaia J, Rossi J, Kurtzberg J, Forman S, Chow R. Cord Blood Transplantation for Long Term Management or Possible Cure of HIV Infection. ASBMT Biology of Blood and Marrow Transplant 2012;16:S215-216. Poster

25. Gyurkocza B, Gutman J, Nemecek ER, Sickle E, Bar M, Baumgart J, Storer B, Appelbaum F, Deeg HJ. Prospective Phase II Multicenter Study of Conditioning with Treosulfan, Fludarabine and Low-dose (2 Gy) Total Body Irradiation followed by Hematopoietic Cell Transplantation from Related or Unrelated Donors for Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. ASH 2012. Oral

26. White JT, Kurche JS, Gutman JA,* Kedl RM.* Varying frequencies of T cells exhibiting CMV peptide-specific reactivity to allo-MHC are present in cord blood transplant units. AAI 2013. Poster

27. Hohensee SE, Aubrey MT, Gutman J, Freed BM. Persistence of Donor-Derived HLA Antibodies In A Stem Cell Transplant Recipient. AABB 2013. Poster

28. Salit RB, Milano F, Gutman JA, Maris MB, Chauncey T, Petersen F, and Delaney C. Umbilical Cord Blood Transplant Patients At High Risk Of Graft Rejection Achieve Early Full Donor Chimerism When 300cGy Is Used In The Reduced Intensity Conditioning Regimen. ASH 2013. Oral

29. Delaney C, Milano F, Nicoud I, Heimfeld S, Karanes C, Gutman J, Wagner J, Appelbaum F, Bernstein I. Overcoming delayed neutrophil recovery in cord blood transplantation by infusion of cord blood progenitors ex vivo expanded in the presence of Notch ligand: Results from a multi-center phase I trial. ASH 2013. Oral

30. Gutman JA, Schmidt C, Freed B, Palmer B. PD-1 expression on total and CMV-specific T cells early transplant is associated with donor source, T cell maturation profile and effectiveness of CMV control. ASH 2013. Poster

31. Gavin K, Kohrt W, Gutman J, Majka S, and Klemm D. De Novo Generation of Adipocytes from Bone Marrow in Human Adipose Tissue. Keystone Obesity Conference 2014. Oral

32. Gutman JA, Myint H, Lee CK, Smith C, Nguyen V, Pollyea DA. Graft Versus Host Disease and Immunosuppression Burden Is Significantly Lower Following Adult Cord Blood Transplantation Versus Matched Unrelated Donor Transplantation. ASBMT 2014. Oral

33. Gutman JA, Myint H, Lee CK, Smith C, Nguyen V, Milano F, Salit R, Delaney C, Pollyea DA. Graft Versus Host Disease and Immunosuppression Burden Is Significantly Lower Following Adult Cord Blood Transplantation Versus Matched Unrelated Donor Transplantation. International Cord Blood Conference 2014. Oral

34. Pollyea DA, Coutre SE, Gore L, Adler N, Harris P, Phelps M, Johnson AJ, Ling Y, Li H, Gutman JA, John C. Byrd JC. A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ASH 2014. Poster

35. Pollyea DA, Smith C, Nguyen V, Fullerton A, Schatz D, Bedrick E, Gutman JA. Sequential azacitidine and high-dose lenalidomide for relapsed and refractory high-risk MDS and AML: Interim analysis of a phase 2 study. ASH 2014. Poster

36. Gutman JA, Denoncourt E, Schatz D, Tailor S, Smith C, Pollyea DA. A Phase 2 Study of the Hedgehog Pathway Smoothened Inhibitor PF-04449913 to Reduce Relapse in High Risk Acute Leukemia and MDS Patients Following Allogeneic Transplantation. ASBMT 2015. Poster

37. IHC Analysis and Prognostic Factors in Post Transplant Lymphoproliferative Disorders after Solid Organ Transplantation: A Single Center Experience. Nooruddin Z, Robinson W, Pollyea D, Gutman JA, Smith C, Pan Z, Jordan CT, Rabinovitch R, Schowinsky J, Lu X, Ney D, Kamdar M. ASH Blood 2015 126:1443. Poster

38. Haverkos BM, Schowinksy J, Kaplan JB, Kamdar M, Saad A, Ganguly S, Flowers M, Fenske T, Hari P, Hamadani M, Lowsky R, Andritsos L, Gutman J, Devine S. Severe acute graft versus host disease may complicate use of checkpoint blockade after allogeneic stem cell transplant in lymphoma patients. ASH Lymphoma Biology 2016.

39. Haverkos BM, Schowinksy J, Kaplan JB, Kamdar M, Kanate AS, Saad A, Ganguly S, Flowers M, Fenske TS, Hari P, Hamadani M, Lowsky R, Andritsos L, Jagasia M, Brown S, Armand P, Merryman R, Bachanova, V, Stephens D, Nakamura R, Gutman J, Devine SM. Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease. ASH 2016. Oral

40. Sandmaier BM, Maloney DG, Storer B, Olesen G, Maris M, Gutman J, Petersen SL, Langston A, Chauncey T, Bethge WA, Pulsipher MA, Kornblit B, Woolfrey A, Mielcarek M, Martin P, Flowers ME, Storb RF. Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial. ASH 2016. Oral

41. Sorror ML, Sandmaier BM, Storer B, Chauncey T, Shizuru J, Franke GN, Pulsipher M, Maris M, Bruno B, Andersen NS, Hari P, Langston A, Agura E, Sahebi F, Maziarz FR, Petersen F, Bethge W, Gutman J, Olesen G, Yeager A, Hubel K, Hogan W, Mielcarek M, Georges G, Maloney DG, Storb R. ,Allogeneic Hematopoietic Cell Transplantation (HCT) in the Eighth Decade of Life: How Much Does Age Matter? ASBMT 2016. Oral

42. Moyer, G; Gutman, J; DiPaola, J; Buckner, T. Incidence and characteristics of venous thromboemboli among patients undergoing allogeneic stem cell transplantation with umbilical cord blood: A preliminary analysis. HTRS 2017. Oral

43. Sharma P, Pollyea D, Smith C, Purev E, Kamdar M, Haverkos B, Sherbenou D, Gutman, J. Outcomes of Thiotepa Based Reduced Intensity Conditioning Versus Standard Reduced Intensity Conditioning in Adult Patients Undergoing Double Unit Cord Blood Hematopoietic Stem Cell Transplant. EHA. Haematologica 2017; 102(s2)

44. Brett M. Stevens, Amanda Winters, Jonathan A Gutman, Aaron Fullerton, Gregory Hemenway, Nicholas Miltgen, Qi Wei, Taher Abbasi, Shireen Vali, Neeraj Kumar Singh, Leylah M. Drusbosky, Chris R. Cogle, Andrew Hammes, Craig T. Jordan, and Daniel A. Pollyea. Sequential Azacitidine (Aza) and Lenalidomide (Len) for Patients (Pts) with Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML): Clinical Results and Predictive Modeling Using Computational Analysis and Serial Genomics. ASH 2017. Poster

45. Daniel A. Pollyea, Brett M. Stevens, Amanda Winters, Mohd Minhajuddin, Jonathan A Gutman, Enkhtsetseg Purev, Clayton Smith, Diana Abbott and Craig T. Jordan. Venetoclax (Ven) with Azacitidine (Aza) for Untreated Elderly Acute Myeloid Leukemia (AML) Patients (Pts) Unfit for Induction Chemotherapy: Single Center Clinical Experience and Mechanistic Insights from Correlative Studies. ASH 2017. Oral

46. Amanda C. Winters, Madeline Goosman, Brett Stevens, Enkhtsetseg Purev, Clayton Smith, Daniel A. Pollyea, Craig T. Jordan*, Jonathan Gutman* (*co-senior authors) Tracking of AML-Associated Mutations via Droplet Digital PCR is Predictive of Outcomes Post-Transplant. ASH 2018. Poster

47. Prashant Sharma, Enkhtsetseg Purev, Bradley M. Haverkos, Daniel A Pollyea, Clayton Smith, Manali Kamdar, Daniel W Sherbenou, Tomer M Mark, Peter A Forsberg and Jonathan Gutman. Chronic Graft Versus Host Disease Burden and Relapse Rates Are Lower with Comparable Overall Survival and Graft Versus Host Disease Free, Relapse Free Survival Following Adult Umbilical Cord Blood Compared to Matched Sibling Peripheral Blood Stem Cell Transplantation. ASH 2018. Poster

48. Prashant Sharma, MD, Jennifer MacDonald, Jeff Kaiser, Jennifer Tobin, Matthew Miller, Maheen Abidi, Esther Benamu, Enkhtsetseg Purev, Bradley M. Haverkos and Jonathan A Gutman. Post Transplant Prophylaxis with High Dose Valacyclovir through Day 100 Versus Day of Post Transplant Hospital Discharge Decreases Cytomegalovirus Reactivation in Adult Umbilical Cord Blood Transplant Recipients. ASH 2018. Poster

49. Pollyea DA, Jones CL, Stevens B, Pei S, D'alessandro A, Hill R, Abbott D, Hammes A, Dugan J, Gutman J, Purev E, Smith C, Jordan C. Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1. ASH 2018. Oral.

50. Jessica Lum, Enkhtsetseg Purev, Jonathan Gutman, Kelsey Melander, J. David Beckham, Maheen Z. Abidi. Successful reduced intensity stem cell transplant in a patient with myeloproliferative neoplasm/myelodysplastic overlap syndrome diagnosed with West Nile virus encephalitis. ASBMT 2019. Poster

51. Taylor Morrisette, Amanda Van Matre, Matthew A. Miller, Scott W. Mueller, Valida Bajrovic, Jeffrey N. Kaiser, Gerard R. Barber, Douglas N. Fish, Jonathan A. Gutman. Oral Vancomycin Prophylaxis as Secondary Prevention for Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplant and Hematologic Malignancy Population. MAD-ID 2019.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download